Life Sciences

  • September 25, 2026

    Del. Chancery Says Curonix Owns Stimwave Shares

    The medical device company Curonix LLC has won its lawsuit against the founder of Stimwave Technologies Inc., with Delaware's Court of Chancery finding that the plaintiff is the rightful holder of 75,000 shares of the company it purchased in bankruptcy.

  • September 25, 2026

    Cooley, Latham Steer RNA Drugmaker's Upsized $446M IPO

    San Diego-based biotechnology company ADARx Pharmaceuticals began trading publicly on Friday after raising $446 million in its initial public offering steered by Cooley LLP and Latham & Watkins LLP, adding to the growing list of biotech IPOs recently.

  • September 25, 2026

    Novo Bets $1.3B On Nanexa Drug Tech Amid Obesity Push

    Novo Nordisk has agreed to pay up to about €1.165 billion ($1.3 billion) under an exclusive license and collaboration agreement for Swedish drug-delivery company Nanexa's PharmaShell technology.

  • September 25, 2026

    Taxation With Representation: Kirkland, Latham, McDermott

    In this week's Taxation With Representation, Royal Caribbean invests billions in a joint venture with Sandals, Telix Pharmaceuticals buys ITM Isotope Technologies Munich, and Priority Technology makes a go-private deal with an investor group helmed by the company's chair and CEO.

  • September 24, 2026

    Jurisdictional Skepticism Puts Eli Lilly Appeal On Thin Ice

    Eli Lilly & Co.'s bid to unwind the U.S. Food and Drug Administration's refusal to classify a developing obesity treatment as a biological product appears to suffer from jurisdictional issues that might sink the company's appeal before its resolved, a Seventh Circuit judge signaled Thursday.

  • September 24, 2026

    ITC Takes On Patents, Trade Secrets In Large Decision Drop

    The U.S. International Trade Commission issued a flood of decisions this week on investigations in which imports are being evaluated to see if they infringe patents or misappropriate secrets, including three cases where it will reconsider holdings from administrative law judges.

  • September 24, 2026

    Squires Grants 5 Patent Review Bids, Rejects 6 Others

    In his latest round of decisions, U.S. Patent and Trademark Office Director John Squires has granted five petitions seeking reviews of patents, while turning down six other requests: three for discretionary reasons and three on the merits.

  • September 24, 2026

    FDA Nom Says Vaccines Safe, Won't Call IUDs Birth Control

    President Donald Trump's nominee to lead the U.S. Food and Drug Administration faced a Senate committee Thursday morning, where she affirmed the safety of vaccines when pressed but refused to directly contradict the president's false claim that the measles vaccine could be "quite lethal," and declined to affirm that IUDs are birth control and not abortifacients.

  • September 24, 2026

    Mylan Wants Del. Judge To Clear Wegovy Generic Drug

    Mylan Pharmaceuticals Inc. has launched a lawsuit in Delaware federal court asking for a finding that its proposed generic version of Novo Nordisk Inc.'s blockbuster weight loss drug Wegovy does not infringe a patent, the latest salvo in a larger intellectual property fight over the GLP-1.

  • September 24, 2026

    Novartis Beats Patent Listing Suit Over Entresto

    A New York federal judge gave Novartis permanent relief from a proposed class action alleging it monopolistically delayed generic competition for its blockbuster heart failure drug Entresto, concluding that the drugmaker properly used a patent to ensure exclusivity.

  • September 24, 2026

    Eli Lilly Hit With $90M Verdict In Nektar's Rezpeg Breach Suit

    A California federal jury on Thursday found Eli Lilly breached the implied covenant of good faith and fair dealing in an agreement to co-develop Nektar Therapeutics' autoimmune-disease drug Rezpeg, awarding Nektar $90 million — a considerable sum that fell short of the $1 billion the clinical-stage biotech company had sought.

  • September 24, 2026

    Labcorp Inks $2.3M Deal To Resolve Multistate Data Breach

    Labcorp will pay nearly $2.3 million and adopt data security changes under a multistate settlement resolving investigations into a 2019 breach at its former debt collection vendor, a group of state attorneys general announced Thursday.

  • September 24, 2026

    EPA Cuts Deal To Partially Settle U. Of Calif. Grant Fight

    University of California researchers urged a California federal judge Wednesday to preliminarily sign off on their proposed deal to resolve claims against the U.S. Environmental Protection Agency in broader litigation challenging the Trump administration's termination of thousands of UC grants.

  • September 24, 2026

    Thriving Rivals Disprove Hillrom Antitrust Suit, 3rd Circ. Told

    Hill-Rom Holdings Inc. told the Third Circuit on Thursday a Pennsylvania hospital had no evidence the equipment supplier illegally sidelined competitors from the hospital bed market, noting its deals tying discounts to exclusivity hadn't put multiple rivals out of business.

  • September 23, 2026

    Organ Network Says Kidney Race Bias Claims Can't Proceed

    The United Network for Organ Sharing is seeking to exit a proposed class action claiming it prolonged wait times for Black patients seeking kidney transplants by encouraging hospitals to use a flawed race-based adjustment when measuring kidney function, saying the network's policy was "silent" as to how such scores were calculated.

  • September 23, 2026

    Colo. Judge Declines To Sanction Hospital In Gender Care Suit

    Children's Hospital Colorado properly complied with an injunction prohibiting it from refusing to provide medically necessary gender-affirming care to transgender youth patients, a state judge ruled, rejecting a request by a class of patients to hold the hospital in contempt.

  • September 23, 2026

    Patients Drop Fertility Fraud Suits Against Yale Medical School

    Five plaintiffs have dropped two related court actions against Yale School of Medicine, Yale New Haven Hospital and the estate of a Connecticut doctor accused of fraudulently using his own sperm to inseminate fertility patients, state court records show.

  • September 23, 2026

    Curium Resets FTC Clock On $8B Lantheus Take-Private Deal

    Private equity-backed radiopharmaceutical company Curium reset the clock for the Federal Trade Commission's 30-day review of its plan to acquire fellow radiopharmaceutical company Lantheus Holdings Inc. in an $8 billion take-private deal.

  • September 23, 2026

    Vein Tech Maker Escapes Suit Over DOJ Kickback Probe

    A New York federal judge has tossed, for now, a proposed investor class action alleging that vein disease device maker Inari Medical Inc.'s share price fell after it disclosed an investigation into its compliance with federal anti-kickback laws, finding the suit does not plausibly show Inari was paying healthcare providers unlawful kickbacks, among other things.

  • September 23, 2026

    Motley Rice Partner Tapped For Opioid Case Co-Lead Counsel

    The Ohio federal judge overseeing multidistrict opioid litigation appointed on Wednesday Donald Migliori, a managing partner at Motley Rice LLC, as co-lead counsel in the wake of the death of the firm's co-founder Joe Rice, who had served in the position for the past eight years.

  • September 23, 2026

    Vividion Investor Wants IP Suit Over $2B Bayer Deal Revived

    CHP III LP urged the Delaware Supreme Court on Wednesday to revive its suit over allegedly diverted intellectual property in Vividion Therapeutics Inc.'s $2 billion sale to Bayer Corp., while the defendants argued the investor is trying to turn a corporate injury into a direct stockholder claim that did not survive the merger.

  • September 23, 2026

    Legal Groups Back Firm In NC High Court Malpractice Appeal

    Legal advocacy groups are standing behind the law firm Hedrick Gardner Kincheloe & Garofalo LLP in asking North Carolina's highest court to find that the state's four-year statute of repose on legal malpractice claims creates an immovable end-date to liability.

  • September 23, 2026

    Chinese Medicinal Chemical Exporter Faces Triple-Digit Duty

    A pharmaceutical compound imported from China has been found to have been subsidized, and at least one exporter of the goods in question could face triple-digit retroactive countervailing duties, according to a notice issued Wednesday by the U.S. Department of Commerce.

  • September 23, 2026

    DOJ Pressed On Gender Care Ban In Federal HIV Program

    A Massachusetts federal judge on Wednesday skeptically questioned the Trump administration's authority to prohibit doctors from providing gender-affirming care as part of a longstanding, federally funded HIV program.

  • September 22, 2026

    UMass Hospital Co. Beats Ex-VP's COVID Vaccine Firing Claim

    A jury cleared a central Massachusetts hospital system of liability for terminating a compliance officer who refused a COVID-19 shot, finding Tuesday she failed to show a sincere religious belief against vaccination.

Expert Analysis

  • NC Dental Review Change Counters Tougher National Trend

    Author Photo

    North Carolina’s elimination of its prior review requirement for dental management agreements departs sharply from the national trend toward expanded corporate practice of medicine oversight, but stakeholders should not view this regulatory shift as a relaxation of compliance expectations, say attorneys at Holland & Knight.

  • NY Bill Would Boost Litigation Risk For Cosmetics Cos.

    Author Photo

    The Beauty Justice Act, now pending in the New York Legislature, would not only present compliance challenges for companies making cosmetics and personal care products, but could also be used by private plaintiffs to bring consumer fraud, false advertising, toxic exposure and product liability claims, says Kadeejah Kelly-Previl at Faegre Drinker.

  • How To Structure Protective Order AI Provisions In IP Disputes

    Author Photo

    A survey of protective orders in recent intellectual property litigation reveals best practices for drafting provisions on artificial intelligence use that maximize IP protection while balancing enforceability with efficient discovery, say Matthew Stephens and Bryce Tabbut at MoFo.

  • Appellate Vape Rulings May Expand State Regulation Powers

    Author Photo

    Two recent federal appeals courts decisions rejecting Federal Food, Drug and Cosmetic Act preemption challenges to state electronic nicotine delivery systems directory laws signal an emerging appellate consensus that could significantly expand states' power to regulate vaping product sales where federal enforcement falls short, say attorneys at Troutman.

  • 5 Lessons For VC Investors From Del. IPO Ruling

    Author Photo

    The Delaware Court of Chancery's recent dismissal of Rostov v. Alcon Research, a derivative action over a proposed initial public offering, provides multiple practice pointers for venture capital investors, including the importance of precisely worded corporate documents and pleading a coherent theory of corporate harm, says Ben Dubin at VC Expert Services.

  • Fed. Circ. Rulings Emphasize Adjudicative Access And Review

    Author Photo

    Decisions from the Federal Circuit's 2026 docket indicate that the court is increasingly paying attention to whether tribunals possess authority to act, meaning practitioners will need to properly address procedural hurdles before they can argue the merits of a case, say attorneys at Reichman Jorgensen.

  • Series

    Being In A Band Made Me A Better Lawyer

    Author Photo

    Playing shows in storied New York City venues and rehearsing with my bandmates in poorly ventilated rooms helped develop the professional qualities I rely on as a litigator, including an ability to collaborate with strong-minded equals and the determination to treat each client with singular focus, says Eliad Shapiro at Herrick Feinstein.

  • 10th Circ. Ruling Undermines False Ad 'Two Clicks' Rule

    Author Photo

    The Tenth Circuit’s recent ruling in KetoNatural Pet Foods v. Hill's Pet Nutrition substantially challenges a long-standing assumption that a company can avoid responsibility for promotional claims simply because the consumer encountered them by clicking a hyperlink to a third-party website, say attorneys at Venable.

  • How Drug Trial Prediction Markets Pose Insider Trading Risks

    Author Photo

    Multiple prediction market platforms have recently announced plans to offer event contracts related to clinical trial outcomes and regulatory decisions, creating new insider trading risks by expanding the group of people possessing related material nonpublic information far beyond traditional corporate insiders, say attorneys at King & Spalding.

  • Mich. Ruling Gives Consumer Protection Law Its Teeth Back

    Author Photo

    The Michigan Supreme Court's recent decision in Attorney General v. Eli Lilly, overruling key holdings in two earlier cases, means that Michigan businesses can no longer defeat allegations of deceptive conduct under the state's consumer protection law simply by pointing to any governmental regulation of the business, say attorneys at DiCello Levitt.

  • Series

    Law School's Missed Lessons: Surviving A Long Trial

    Author Photo

    Most of law school trial advocacy is geared toward the sprint of trying a short case, but beyond managing a cross-examination or closing argument, effectively handling the marathon of a lengthy trial requires the ability to maintain composure, organization and credibility with the jury, says Mihir Elchuri at Hirschler.

  • AI Chatbot's Medical Claims Highlight Enforcement Risks

    Author Photo

    The Pennsylvania State Board of Medicine's recent lawsuit against Character Technologies, arguing that an artificial intelligence chatbot engaged in the unlicensed practice of medicine, may provide other state licensing boards with a road map for going after AI platforms, and counsel should advise clients to calibrate compliance accordingly, say attorneys at Cooley.

  • 7th Circ. Ruling May Reduce Litigation Risk For Text Marketers

    Author Photo

    The recent Seventh Circuit holding in Steidinger v. Blackstone Medical Services that unwanted marketing text messages are not telephone calls under the Telephone Consumer Protection Act may strengthen companies' responses to presuit demand letters and early-stage litigation claims premised on do-not-call text theories, say attorneys at Holland & Knight.

  • How Calif. Ruling Defines Drug Cos.' R&D Responsibilities

    Author Photo

    The California Supreme Court's recent ruling in the Gilead Tenofovir Cases, which held that drugmakers have no duty to bring allegedly safer alternatives to market more quickly, is a win for pharmaceutical companies — but not a grant of blanket immunity for all early-stage drug development decisions, say attorneys at King & Spalding.

  • Midyear Trends, Takeaways As Securities Class Actions Surge

    Author Photo

    High numbers of securities class actions through June suggest filings will stay elevated, with factors like changing enforcement attitudes, media scrutiny and the proliferation of potential defendants serving as both cause and effect in increased litigation involving AI-related disclosures, health and tech companies, and foreign issuers, say attorneys at Alston & Bird.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.